These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2509207)

  • 1. Schedule and dosage modification of a cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin combination chemotherapy regimen for refractory ovarian cancer.
    Bruckner HW; Cohen CJ; Bhardwaj S; Feuer E; Chesser MR; Holland JF
    Eur J Cancer Clin Oncol; 1989 Sep; 25(9):1273-9. PubMed ID: 2509207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen.
    Bruckner HW; Cohen CJ; Feuer E; Holland JF
    Obstet Gynecol; 1989 Mar; 73(3 Pt 1):349-56. PubMed ID: 2492648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
    Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
    Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
    Levin L; Simon R; Hryniuk W
    J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
    Greco FA; Johnson DH; Hainsworth JD
    Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hexamethylmelamine for the treatment of ovarian cancer--the Mount Sinai experience.
    Bruckner HW; Cohen C; Mandeli J; Chesser MR; Kabakow B; Wallach R; Holland J
    Cancer Treat Rev; 1991 Mar; 18 Suppl A():57-65. PubMed ID: 1904310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
    Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Kooyman CD; van Lindert AC; Hamerlynck JV; van Lent M; van Houwelingen JC
    Lancet; 1984 Sep; 2(8403):594-600. PubMed ID: 6147640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for ovarian adenocarcinoma.
    Piver MS; Lele S; Barlow JJ
    Cancer Treat Rep; 1981; 65(1-2):149-51. PubMed ID: 6784921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
    Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
    Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
    [No Abstract]   [Full Text] [Related]  

  • 11. Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer.
    Bruckner HW; Cohen CJ; Goldberg JD; Kabakow B; Wallach RC; Deppe G; Reisman AZ; Gusberg SB; Holland JF
    Am J Obstet Gynecol; 1983 Mar; 145(6):653-8. PubMed ID: 6402934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma.
    Kane R; Harvey H; Andrews T; Bernath A; Curry S; Dixon R; Gottlieb R; Kukrika M; Lipton A; Mortel R; Ricci J; White D
    Cancer Treat Rep; 1979 Feb; 63(2):307-9. PubMed ID: 109201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors: cisplatin regimens for patients with ovarian cancer after failure of chemotherapy.
    Bruckner HW; Cohen CJ; Feuer E; Wallach RC; Kabakow B; Holland JF
    Obstet Gynecol; 1987 Jan; 69(1):114-20. PubMed ID: 3099235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
    Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Willemse PH; Heintz AP; van Lent M; Trimbos JB; Bouma J; Vermorken JB
    J Clin Oncol; 1987 Aug; 5(8):1157-68. PubMed ID: 3114434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification.
    Coleman M; Pasmantier MW; Silver RT
    Cancer; 1985 May; 55(10):2342-7. PubMed ID: 3921228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of advanced ovarian cancer with sequential combination chemotherapy.
    Griffin TW; Hunter RA; Cederbaum AI; Tak WK; Ward AD; Schwartz JH; Halpin TF; Strauss GM; Meyer RN; Liepman MK
    Cancer; 1987 Nov; 60(9):2150-5. PubMed ID: 2830953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer.
    Levin L; Hryniuk W
    Semin Oncol; 1987 Dec; 14(4 Suppl 4):12-9. PubMed ID: 3120317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract.
    Jansen RL; van der Burg ME; Verweij J; Stoter G
    Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1131-3. PubMed ID: 3115787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.